Skip to content

A multicenter, prospective, randomized controlled trial for the effects of early implantation of intraaortic balloon counterpulsation in patients with acute myocardial infarction complicating cardiogenic shock

A multicenter, prospective, randomized controlled trial for the effects of early implantation of intraaortic balloon counterpulsation in patients with acute myocardial infarction complicating cardiogenic shock

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033615
Enrollment
Unknown
Registered
2020-06-07
Start date
2020-06-10
Completion date
Unknown
Last updated
2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction complicating cardiogenic shock

Interventions

Group 1:early implantation of IABP
Group 2:mplantation of IABP if necessary

Sponsors

Hu'nan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with age more than 18 years old and less than 80 years old; 2. Acute myocardial infarction; 3. Cardiogenic shock, which is less than 12 hours before screening; 4. Emergent percutaneous coronary intervention was planned; 5. Signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with resuscitation more than 30 minutes; 2. Patients with no intrinsic heart action; 3. Patients with cerebral deficit with fixed dilated pupils, which are not drug-induced; 4. Patients with mechanical causes of cardiogenic shock such as ventricular septal defect or acute moderate or severe mitral regurgitation; 5. Cardiogenic shock was caused by right ventricular myocardial infarction; 6. Cardiogenic shock was not caused acute myocardial infarction; 7. Acute massive pulmonary embolism; 8. Patients with severe peripheral artery disease precluding IABP insertion; 9. Patients with moderate or severe aortic regurgitation; 10. Patients with other severe concomitant disease with limited life expectancy less than 6 months; 11. Patients with participation in another trial.

Design outcomes

Primary

MeasureTime frame
all-cause mortality;

Countries

China

Contacts

Public ContactZheng Zhaofen

Hu'nan Provincial People's Hospital

zhaofenz@foxmail.com+86 13974829586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026